7/7 #TumorBoardTuesday Thurs Case🎀 🙏Careful discussion & individualized care, IO can be considered in neoadj setting for pts w autoimmune dz 🤔Better biomarkers 🎯 IO in future? 📅08.08: @MMarmarelis @norataranto explore tx after progression on Osimertinib in #EGFR m #NSCLC! (@JohnEbbenMDPhD)

#Clinicaltrial EA5162, led by @ZPiotrowskaMD and @LeciaSequist of @MGHCancerCenter, will evaluate how well osimertinib works in treating pts w/ advanced #NSCLC w/ EGFR ex20-ins mutations. Learn more here: https://t.co/pwy12PyvBr #lcsm (@eaonc)

“Adjuvant Osimertinib Improves Overall Survival in EGFR-Mutated Lung Cancer” presented by Dr Roy S. Herbst and colleagues at the 2023 ASCO Annual Meeting https://t.co/gK0miTQZc6 @DrRoyHerbstYale @ASCO #ASCO23 (@clinadvances)

A multiD intervention (radiology, pathology, pharmacy, & oncology) ⬇️⬇️ time to start osimertinib for pts with #EGFR-mutant #NSCLC (5 vs 23 days) by directly analyzing frozen tissue & engaging pharmacy early: https://t.co/FHkNGChqVK #LungCancer #lcsm @IbiayiMD (@JCOOP_ASCO)

#Clinicaltrial EA5162, led by @ZPiotrowskaMD and @LeciaSequist of @MGHCancerCenter, will evaluate how well osimertinib works in treating pts w/ advanced #NSCLC w/ EGFR ex20-ins mutations. Learn more here: https://t.co/pwy12PyvBr #lcsm (@eaonc)

🧬🎯 promising phase 1/2 vs EGFR ex20ins 🤞 accompanying editorial from @CharuAggarwalMD is 👌 Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Ex20ins https://t.co/bhscPeHnZn (@forbesygordi)

Honored to write an invited editorial on "Zipalertinib in EGFR Exon 20–Mutant NSCLC" - out now in @JCO_ASCO @ASCO @StephenVLiu - we discuss the role of novel TKIs, and drug development in this rare, but increasingly crowded space! Congrats to the authors on this important… https://t.co/q2gu83PHLN (@CharuAggarwalMD)

A targeted therapy drug improved survival in pts w/ #lungcancer who have #EGFR mutations. PC3I's @CharuAggarwalMD provided input for @theNCI: “This confirms our practice to test for EGFR mutations and recommend adjuvant targeted therapy with osimertinib” https://t.co/O3AdUxmIdX (@PC3Innovation)

In a biomarker analysis of cohort D in the CHRYSALIS-2 trial, patients with MET-positive NSCLC achieved an ORR of 61% with amivantamab plus lazertinib vs an ORR of 14% in the MET-negative population. @BenjaminBesseMD @GustaveRoussy @ASCO #ASCO23 #lcsm https://t.co/NsJLrnBlf5 (@OncLive)

From ADAURA Trial: "Osimertinib does NOT replace chemotherapy, when indicated (typically stage II & III NSCLC)". Dr. @Joshua_Reuss #TargetedTherapiesInLungCancer #cancerGRACE (@cancerGRACE)

MET positivity showed predictive value for durable responses with amivantamab plus lazertinib in patients with EGFR-mutated NSCLC whose disease progressed on/after osimertinib and are chemotherapy naïve. @BenjaminBesseMD @GustaveRoussy @ASCO #ASCO23 #lcsm https://t.co/UHG7PDlrer (@OncLive)

Patient with metastatic cholangiosarcoma with mRNA+ her2 (ihc, DNA NA) 24+ ongoing months PR on lapatinib/trastuzumab ⁦@AaronGoodman33⁩ ⁦⁦@BostonGenomics⁩ See Akram at al. JCO PO July 2023. Impressive response predicted by Her2 mRNA (@Dr_R_Kurzrock)

Updates to the @ASCO Living Guidelines on Therapy for Stage IV NSCLC with Driver Alterations now @JCO_ASCO. Additions include amivantamab and mobocertinib for #EGFR exon 20 insertion NSCLC and sotorasib for #KRAS G12C NSCLC. https://t.co/NdWku4z9BU (@StephenVLiu)

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: @ASCO Living Guideline 📌Added update on amivantamab, mobocertinib and sotorasib @JCO_ASCO @OncoAlert https://t.co/VK0ojQpfeM (@dr_yakupergun)

EGFR Inhibition in EGFR–Amplified Gastroesophageal Cancer 60 pts ORR All pts➡️43% ChT plus EGFRi➡️57% mPFS All pts➡️4.6 mo ChT plus EGFRi➡️6.0 mo First line➡️6.9 mo 📌Well-selected patients with EGFR-amplified GEA derive significant benefit from EGFRi @JCO_ASCO… https://t.co/CJfrsAqzMH (@dr_yakupergun)

📢 eNewsletter Top 5 #lungcancer treatments from #ASCO23 1️⃣ ADAURA trial improved OS with adjuvant osimertinib. 2️⃣ Keynote 671 perioperative chemo w/ pembrolizumab. and 3 more @JackWestMD @cancergrace @cityofhope https://t.co/KGGx0d2AGv (@oncologytube)

MET+ Expression May Be Predictive of Responses With Amivantamab/Lazertinib in Post-Osimertinib NSCLC @BenjaminBesseMD @GustaveRoussy @ASCO #ASCO23 #lcsm https://t.co/YpRja7Cdom (@OncLive)

Zipalertinib in Lung Cancer Harboring EGFR Exon 20 Insertions https://t.co/ogKdpiWqFm. Responses seen from starting till the final dose level. Another agent apart from Amivatinab, poziotinib and mobocertinib @JCO_ASCO @LungConnectIN (@DrVijayPatil11)

1. First in man study of gleevec in CML. 2. Discovery of EGFR mutations in patients who respond to gefitinib. 3. Whole genome sequencing of the first AML genome. (@rosslevinemd)

Here is what happened to 73 patients with EGFR exon20 insertions treated with Zipalertinib in a phase I/2a study. #lcsm @ZPiotrowskaMD https://t.co/e7nwt4FYFd (@DrewMoghanaki)

WATCH: Benjamin Besse, MD, PhD, discuss the biomarker analysis of the phase 1/1b CHRYSALIS-2 study of amivantamab & lazertinib in EGFR-mutated #NSCLC. #lcsm | @BenjaminBesseMD @GustaveRoussy https://t.co/HefAm5R0C8 (@TargetedOnc)

Case report of a patient with #EGFR mutant NSCLC who developed an acquired #BRAF V600E mutation on osimertinib as well as leptomeningeal disease and achieved durable control with osimertinib, dabrafenib, and trametinib. #JTOCRR @JTOonline https://t.co/TcycKvLI9x (@StephenVLiu)

In Spain we cannot give dabra + trame for BRAF V600E mutant NSCLC, so, imagine for a patient that develop this mutation as a mechanism of resistance to osimertinib 😓 (@BoschBarrera)

Befotertinib another third gneration agent in EGFR mutated NSCLC @Bhosale26Bharat @AshayKarpe59998 @Nandinimenon18 https://t.co/1B3U8IKTTd (@DrVijayPatil11)

Zipalertinib Among Patients With NSCLC +Exon 20 Insertions @ZPiotrowskaMD et al. Previously treated 💊Phase 1/2A (n=73) 💊PR 41% (16/39) 💊TRAEs : rrash (80%), paronychia (32%), diarrhea (30%), no grade 3 @EGFRResisters #lcsm https://t.co/sezkKjc9PK (@Latinamd)

If we are talking about an early survival advantage with adjuvant osimertinib, it depends how big the advantage is and how long it lasts. In a bad disease like metastatic pancreas cancer, a 10% survival advantage for a few months would be great! (@VoglNY)

Panitumumab plus TAS as anti-EGFR rechallenge therapy in refractory RAS WT #CRC: OS & subgroup analysis of the randomized VELO trial at #WCGIC2023 👉rechallenge with anti-EGFR seems to be effective 👉PFS improved 👉no OS benefit, but 50% crossover @WCGIC @myESMO @OncoAlert (@ArndtVogel)

Results from phase I/II study of zipalertinib (CLN-081) in #EGFR exon 20 insertion NSCLC @JCO_ASCO. RR 38%; TRAEs include rash (80%), paronychia (32%), diarrhea (30%). At a zipalertinib dose of 100mg bid (oral), RR was 41% and no G3+ rash/diarrhea. https://t.co/S2OkALQNb8 (@StephenVLiu)

Benjamin Besse, MD, PhD, discussed phase 1/1b CHRYSALIS-2 data of amivantamab + lazertinib in EGFR-mutated #NSCLC. #lcsm | @BenjaminBesseMD @GustaveRoussy https://t.co/zlllgfab3r (@TargetedOnc)

Lazertinib vs Gefitinib as First-line Treatment in Patients with EGFR-mutated advanced NSCLC: LASER301 Lazertinib vs Gefitinib mPFS➡️20.6 vs 9.7 mo ORR➡️76% vs 76% mDOR➡️19.4 vs 8.3 mo 18-m OS➡️80% vs 72% @JCO_ASCO @OncoAlert https://t.co/62K6Lo7F2q (@dr_yakupergun)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and @Alfdoc2 discuss the ADAURA trial, which studied patients with resected or resectable stage IB-IIIA EGFR+ NSCLC who were given Tagrisso. https://t.co/2MhWMPw15a (@cancerGRACE)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and @Alfdoc2 look at data on Sunvozertinib's use against EGFR Exon 20 NSCLC. https://t.co/xvqYxoFOok For more, please visit https://t.co/7Xpzj7KaFx. (@cancerGRACE)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and @Alfdoc2 examine treatment options for patients with EGFR+ disease, who also have acquired resistance to EGFR inhibitor therapy. https://t.co/ACk8XmNvu3 (@cancerGRACE)

Adjuvant #Osimertinib for Resected #EFGR-Mutated Stage Ib-IIIA #NSCLC 👉https://t.co/MCA6HmcVuj @ASCO #LungCancer #ConferenceHighlights (@davidhenrymd)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and Alfredo Addeo discuss the ADAURA trial, which studied patients with resected or resectable stage IB-IIIA EGFR+ NSCLC who were given Tagrisso. https://t.co/2MhWMPw15a (@cancerGRACE)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and Alfredo Addeo look at data on Sunvozertinib's use against EGFR Exon 20 NSCLC. https://t.co/xvqYxoFOok For more, please visit https://t.co/3VETMT8eM4. (@cancerGRACE)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and Alfredo Addeo examine treatment options for patients with EGFR+ disease, who also have acquired resistance to EGFR inhibitor therapy. https://t.co/ACk8XmNvu3 (@cancerGRACE)

🫁 #Osimertinib 🫁 #ASCO23 Game-Changing Treatment for Non-Small Cell Lung Cancer by @TommyJohn00 @PeterMacCC great video https://t.co/YD9omMYVjp #NSCLC (@oncologytube)

👍 BCA101 🙌 combined with Pembrolizumab video https://t.co/bj62xHP0HP shows positive results in treating metastatic Head and Neck cancer. @HeadNeckMD promising combo therapy brings hope for improved outcomes. #CancerResearch #BCA101 #Pembrolizumab #HeadAndNeckCancer #ASCO23 (@oncologytube)

ADAURA is 1st Ph3 study of a targeted therapy in NSCLC adjuvant setting to show OS benefit ➡️adj osimertinib as SOC for resected EGFR+ NSCLC & EGFR testing in early-stage NSCLC? Let's hear the evidence from @TommyJohn00 at #TOGAASCO23 2nite Register https://t.co/WaGyxidkaR (@TOGAANZ)

Rami Manochakian, MD, on NSCLC: Commentary on the ADAURA Trial of Osimertinib https://t.co/F7tJRDzJ32 #LCSM #lungcancer #oncology #ASCO23 @RManochakian (@ASCOPost)

#EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR fusion-positive advanced #cholangiocarcinoma https://t.co/jBV3Ozice5 #fondazionebonadonna #cancerresearch #oncology @CarmenCriscit @BianchiniGP @mauricallari (@FondazioneBona1)